← Leaderboards
Wilton B Williams
Duke University
$19,801,567
Attributed
$33,725,743
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.1M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,725,743 · 7
By mechanism
UM1$21,986,953 · 1
R01$8,632,997 · 3
R37$1,624,728 · 1
U01$1,239,565 · 1
R21$241,500 · 1
Top collaborators
- Priyamvada Acharya5 shared
- Guido Ferrari4 shared
- Maria Blasi1 shared
- Todd Christopher Bradley1 shared
- Justin Joseph Pollara1 shared
Most similar at Duke University
Same institution · by research overlap
- Priyamvada Acharya$21,922,845
- Genevieve Giny Fouda Amou Ou$19,482,405
- Rory Henderson$10,557,589
- Kevin Wiehe$11,369,637
- Patrick C. Seed$6,283,538
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseHiv-1Neutralizing AntibodySimian Human Immunodeficiency VirusGrantInnovationVaccinesB-LymphocytesDesignSamplingAntigensImmunologicsImmunityPlasmaEvolutionVirus DiseasesCharacteristicsMacacaAffinityInsightInfectionEpitopesVaccination StrategyVirus
Grant awards (19)
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens$4,630,856
UM1 · FY2025 · AI · contact PI
Mechanisms of Early-life Immunity Associated with HIV-1 Vaccine-induced Neutralizing Antibody Responses$1,239,565
U01 · FY2025 · AI · contact PI
Neonatal Immunity to novel TF SHIVs$800,666
R37 · FY2025 · AI · contact PI
Persistent Immunogenicity of IDLV delivering Gag and membrane tethered HIV-1 Envelope Trimers$791,661
R01 · FY2025 · AI
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1$661,066
R01 · FY2025 · AI
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens$5,733,658
UM1 · FY2024 · AI · contact PI
Neonatal Immunity to novel TF SHIVs$824,062
R37 · FY2024 · AI · contact PI
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1$672,175
R01 · FY2024 · AI
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens$5,902,563
UM1 · FY2023 · AI · contact PI
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1$683,445
R01 · FY2023 · AI
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens$5,719,876
UM1 · FY2022 · AI · contact PI
Neonatal Immunity to novel TF SHIVs$751,002
R01 · FY2022 · AI · contact PI
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1$695,359
R01 · FY2022 · AI
Neonatal Immunity to novel TF SHIVs$1,336,670
R01 · FY2021 · AI · contact PI
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1$704,939
R01 · FY2021 · AI
Molecular signatures of broad neutralization in HIV infected children$241,500
R21 · FY2021 · HD · contact PI
Neonatal Immunity to novel TF SHIVs$765,777
R01 · FY2020 · AI · contact PI
Neonatal Immunity to novel TF SHIVs$797,005
R01 · FY2019 · AI · contact PI
Neonatal Immunity to novel TF SHIVs$773,898
R01 · FY2018 · AI · contact PI